Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 18/9/2019
SIETES contiene 92806 citas

 
 
 1 a 20 de 142 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Walsh LK, Donelle J, Dodds L, Hawken S, Wilson K, Benchimol EI, Chakraborty P, Guttmann A, Kwong JC, MacDonald NE, Sprague AE, Top KA, Walker MC, Web SW, Fell DB. Health outcomes of young children born to mothers who received 2009 pandemic H1N1 influenza vaccination during pregnancy: retrospective cohort study. BMJ 2019;366:10 de julio. [Ref.ID 103171]
2.Enlace a cita original Cita con resumen
Bekkering GE, Agoritsas T, Lytvyn L, Heen AF, Feller M, Moutzouri E, Abdulazeem H, Aertgeerts B, Beecher D, Brito JP, Farhoumand PD, Ospina NS, Rodondi N, van Driel M, Wallace E, Snel M, Okwen PM, Siemieniuk R, Vandvik PO, Kuijpers T, Vermandere M. Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline. BMJ 2019;365:14 de mayo. [Ref.ID 103122]
3. Cita con resumen
Sheppard JP, Stevens S, Stevens R, Martin U, Mant J, Richard Hobbs FD, McManus RJ. Benefits and harms of antihypertensive treatment in low-risk patients with mild hypertension. JAMA Intern Med 2018:29 de octubre. [Ref.ID 102837]
4.Enlace a cita original Cita con resumen
Baillargeon J, Kuo YF, Westra JR, Urban RJ, Goodwin JS. Testosterone prescribing in the United States, 2002-2016. JAMA 2018;319:10 de julio. [Ref.ID 102792]
5. Cita con resumen
Thielking M. FDA cracks down on ‘vaginal rejuvenation’ devices, citing potential for serious harm. STAT Daily Recap 2018:30 de julio. [Ref.ID 102728]
7. Cita con resumen
Anónimo. FDA approves first drug to reduce excessive sweating. DIA Daily 2018:1. [Ref.ID 102699]
8. Cita con resumen
Adlington K. Pop a million happy pills? Antidepressants, nuance, and the media. BMJ 2018;360:9 de marzo. [Ref.ID 102479]
9.Tiene citas relacionadas Cita con resumen
Summerfield D. NHS antidepressant prescribing: what do we get for £266m a year?. BMJ 2018;360:k1019. [Ref.ID 102475]
10.Enlace a cita original Cita con resumen
Huybrechts KF, Bröms G, Christensen LB, Einarsdóttir K, Engeland A, Furu K, Gissler M, Hernández-Díaz S, Karlsson P, Karlstad Ø, Kieler H, Lahesmaa-Korpinen AM, Mogun H, Nørgaard M, Reutfors J, Sørensen HT, Zoega H, Bateman BT. Association between methylphenidate and amphetamine use in pregnancy and risk of congenital malformations: a cohort study from the international pregnancy safety study consortium. JAMA Psychiatry 2017:13 de diciembre. [Ref.ID 102188]
11. Cita con resumen
Montastruc J-L. A propos du Levothyrox® : les réflexions du pharmacologue médical. BIP31.fr 2017;24:60. [Ref.ID 102182]
12. Cita con resumen
Anónimo. Finasteride: rare reports of depression and suicidal thoughts. Drug Safety Update 2017;10:2-3. [Ref.ID 101600]
13. Cita con resumen
15.Tiene citas relacionadas Cita con resumen
Jaspers L, Feys F, Bramer WM, Franco OH, Leusink P, Laan ETM. Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women: a systematic review and meta-analysis. JAMA Intern Med 2016;176:453-62. [Ref.ID 100198]
16.Tiene citas relacionadas Cita con resumen
Woloshin S, Schwartz LM. US Food and Drug Administration approval of flibanserin: even the score does not add up. JAMA Intern Med 2016;176:439-42. [Ref.ID 100197]
17. Cita con resumen
Joffe HV, Chang C, Sewell C, Easley O, Nguyen C, Dunn S, Lehrfeld K, Lee L, Kim MJ, Slagle AF, Beitz J. FDA approval of flibanserin — Treating hypoactive sexual desire disorder. N Engl J Med 2016;374:101-4. [Ref.ID 100089]
18. Cita con resumen
Anónimo. Valeant “predatorily priced” female libido drug, investors claim. DIA Daily 2016:1. [Ref.ID 100042]
19. Cita con resumen
Cheungpasitporn W, Thongprayoon C, Mao MA, Srivali N, Ungprasert P, Varothai N, Sanguankeo A, Kittanamongkolchai W, Erickson SB. Hypomagnesaemia linked to depression: a systematic review and meta-analysis. Internal Medicine Journal 2015;45:436-40. [Ref.ID 99741]
20.Tiene citas relacionadas Cita con resumen
Storebo OJ, Krogh HB, Ramstad E, Moreira-Maia CR, Homskov M, Skoog M, Nilausen TD, Magnusson FL, Zwi M, Gillies D, Rosendal S, Groth C, Rasmussen KB, Gauci D, Kirubakaran R, Forsbol B, Simonsen E, Gluud C. Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. BMJ 2015;351:h5203. [Ref.ID 99705]
Seleccionar todas
 
 1 a 20 de 142 siguiente >>